



Trends of cutaneous melanoma in the Netherlands: increasing incidence rates among all 
Breslow thickness categories and rising mortality rates since 1989 
 
L.M. Hollestein 1, S.A.W. van den Akker 2, T. Nijsten 1, H.E. Karim-Kos 2, J.W. Coebergh 2 
E. de Vries 1,2. 
 
1Department of Dermatology, Erasmus MC, Rotterdam, The Netherlands 
2Department of Public Health, Erasmus MC, Rotterdam, The Netherlands 
 
Corresponding author: 
E. de Vries, PhD 
Department of Public Health and department of Dermatology, Erasmus MC 
PO Box 2040, 3000 CA Rotterdam, The Netherlands 
Tel: +31 10 407 77 30; Fax: +31 10 463 84 75 
Email: e.devries@erasmusmc.nl 
 
Key words: melanoma, epidemiology, incidence, mortality, survival 
 
Word count Abstract: 202 
Word count Article:  
 
 
Number of figures: 3 
Number of tables: 2876 
 
The authors have declared no conflicts of interest
 2 
Abstract 
Background: It has been debated that the epidemic of melanoma is largely due to 
overdiagnosis, since increases in incidence were mainly among thin melanomas and mortality 
rates remained stable. Our objective was to examine this controversy in the Netherlands.  
Patients and Methods:  Information on newly diagnosed melanoma patients was obtained 
from the Netherlands Cancer Registry (NCR). European Standardised Rates (ESR) and 
Estimated Annual Percentage Change (EAPC) were calculated for the period 1989-2008. 
Cohort-based, period-based and multivariate survival analyses were performed.  
Results: The incidence rate of melanoma increased with 4.1% (95% CI: 3.6-4.5) annually. 
Incidence rates of both thin melanomas (≤ 1mm) and thick melanomas (> 4 mm) increased 
since 1989. Mortality rates increased mainly in older patients (>65 years). Ten-year relative 
survival of males improved significantly from 70% in 1989-1993 to 77% in 2004-2008 (p < 
0.001) and for females the 10-year relative survival increased from 85% to 88% (p < 0.01). 
Recently diagnosed patients had a better prognosis even after adjusting for all known 
prognostic factors. 
Conclusion: Since incidence of melanomas among all Breslow thickness categories increased 
as well as the mortality rates, the melanoma epidemic in the Netherlands seems to be real and 
not only due to overdiagnosis.   
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Introduction 
Worldwide, almost 200,000 patients are diagnosed with cutaneous melanoma (melanoma) 
each year [1]. Incidence rates are increasing in all countries, except in Australia and Canada 
[2]. Although, incidence rates in Australia remain very high. In the Netherlands the incidence 
of melanoma increased since 1989, the first year of the National Cancer Registry. Incidence, 
mortality and survival of cutaneous melanoma in the Netherlands were described by de Vries 
et al. up to 1998 [3]. Ten years of additional data have become available since these analyses. 
Incidence of all cutaneous malignancies in the Netherlands have recently been described by 
Holterhues et al., indicating that melanoma incidence has almost doubled in 2005 compared 
to 1989 [4]. As melanoma incidence rates are rising in many countries, it is debated if this 
increase represents a real melanoma epidemic or that this might have been caused by 
increased awareness leading to potential overdiagnosis. Overdiagnosis in melanoma could be 
the results of diagnostic drift, which reclassified what were previously found to be benign 
melanocytic nevi as truly malignant melanomas [5-7]. We hypothesized that there is a real 
increase in melanoma incidence and that, therefore, there is a real increase in thin and thick 
melanomas as well as melanoma related mortality. To examine this controversy in the 
Netherlands, incidence rates together with mortality rates and survival of melanoma patients 




Population-based data from the nationwide Netherlands Cancer Registry (NCR), which 
started in 1989 and is maintained and hosted by the Comprehensive Cancer Centres, were 
used [8]. The NCR is based on notification of all newly diagnosed malignancies in the 
Netherlands by the automated pathological archive (PALGA). Additional sources are the 
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national registry of hospital discharge, which accounts up to 8% of new cases, haematology 
departments and radiotherapy institutions. Information on patient characteristics like sex, date 
of birth, and tumour characteristics such as date of diagnosis, subsite (International 
Classification of Diseases for Oncology (ICD-O-3) [9] histology, stage (Tumour Lymph Node 
Metastasis (TNM) classification) [10] are obtained routinely from the medical records. The 
quality of the data is high, due to thorough training of the administrators and computerised 
consistency checks at regional and national levels. Completeness is estimated to be at least 
95%.  Follow-up of vital status of all patients was calculated as the time from diagnosis to 
death or to the 1st of February 2010. The information on vital status was initially obtained 
from municipal registries and from 1995 onwards from the nationwide population registries 
network. These registries provide virtually complete coverage of all deceased Dutch citizens. 
For the present study, all patients with invasive primary cutaneous melanoma (C43) 
diagnosed in the period 1989-2008 in the Netherlands were included (n=45,919). Age was 
divided in three groups (0-44, 45-64, ≥65years). The study period was divided in four 
categories: 1989-1993, 1994-1998, 1999-2003, and 2004-2008 to study trends. TNM was 
determined postoperative. Clinical stage was used in cases where postoperative stage was 
unknown. Tumour localisation was categorised into anatomical subsites: head and neck 
(C43.0, C43.1, C43.2, C43.3, C43.4), trunk (C43.5), arms (C43.6), legs (C43.7), and other 
(C43.8, C43.9). For the period 1989-1994 only survival data of five regional cancer registries 
was available, which are representative for the whole of the Netherlands. Patients younger 
than 15 years and older than 95 years were excluded from the survival analysis, as well as 
cases diagnosed by autopsy.  
Mortality data for the period 1989-2009 was obtained from Statistics Netherlands. 
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Statistical analyses 
Annual incidence and mortality rates for the period 1989-2008 were calculated per 100,000 
person-years, using the annual mid-year population size as obtained from Statistics 
Netherlands. Rates were age-standardised to the European standard population (European 
Standardised Rates (ESR)). Changes were evaluated by calculating the estimated annual 
percentage change (EAPC) and the corresponding 95% confidence interval (CI). To calculate 
this, a regression line was fitted to the natural logarithm of the rates, using the calendar year 
as regressor variable (i.e. y=ax + b where y = ln(rate) and x = calendar year, then EAPC = 100 
* (e a – 1)). Incidence rates were also calculated per sex, age group, histological subtype, 
bodysite and stage.  
Due to changes in staging of melanoma over time, time trends were tested by comparing 
nodular status (N) and metastatic status (M) of the TNM of which the definition remained 
unchanged over time. Breslow thickness was used to test for trends in melanoma thickness 
over time, because classification of tumour thickness (T of TNM) changed over time. Time 
trends in melanoma thickness were calculated for the period 1994-2008, because Breslow 
thickness was routinely registered since 1994. 
Traditional cohort-based 10-year relative survival analysis was used for the period 1989-1998 
which represents the survival of patients diagnosed during 1989-1998. Since follow-up was 
available until January 2010 period-based 10-year relative survival analysis was used for the 
most recent period 1999-2008, which gives the most up-to-date estimates for this period [11]. 
Multivariate relative survival analyses, using Poisson regression modeling, were carried out to 
estimate relative excess risk (RER) of dying adjusted for follow-up interval [12]. Two 
multivariate models were fit; a model without Breslow thickness, covering the whole period 
(1989-2008) and a model with Breslow thickness, excluding the first time period (1989-
1993). SAS software (SAS system 9.2, SAS Institute, Cary, NC) was used to perform the 




The average population size of the Netherlands between 1989 and 2008 was 15.7 million. 
During this 20-year period 19,393 males and 26,526 females were diagnosed with melanoma. 
Between 1989 and 2009 5,840 males and 4,769 females died due to melanoma.  
Trends in incidence 
The age-standardised incidence (ESR per 100,000 person-years) increased from 11.3 in 1989 
to 21.7 in 2008 (EAPC 4.1, 95% CI: 3.6-4.5) [Figure 1]. In table 1 ESR are provided per 
100,000 person-years for four 5-years periods by sex, age, histopathologic subtype, bodysite, 
nodular status, metastatic status and Breslow thickness. For both sexes the highest incidence 
rates were observed in patients older than 65 years. Superficial Spreading Melanoma (SSM) 
was the most commonly diagnosed subtype in males and females and the incidence of this 
subtype increased more rapidly than the incidence of other subtypes (EAPC 7.6, 95% CI: 7.1-
8.2 and 6.5, 95%CI: 6.0-7.0 for males and females, respectively). The trunk was the most 
commonly affected body site in males and the legs were the most commonly affected body 
site in females.  
The incidence of melanoma in each of the 4 Breslow thickness categories increased 
significantly in the study period. Thin melanomas (<= 1mm) increased each year with 7.0% 
and 6.1% for males and females, respectively. Thick melanomas (>4 mm) increased as well, 
with an annual increase of 5.3% for males and 6.5% for females. Thick melanomas increased 
with approximately the same rate as thin melanomas in females. In contrast to Breslow 
thickness and nodal involvement, the presence of systemic metastasis did not increase 
significantly between 1989 and 2008. 
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Trends in  survival 
Over time, a small increase in relative survival was observed for both sexes [Table 2, Figure 
2]. The 10-year relative survival for males increased significantly from 70% in the period 
1989-1993  to 77% in the period 2004-2008 (p < 0.001). In the same period, the 10-year 
relative survival for females increased significantly from 85% to 88% (p < 0.01). The relative 
excess risk (RER) of dying decreased significantly over time for males and females [Table 2].  
Relative survival improved significantly in more recent periods of diagnosis, also after 
adjusting for age, histological subtype, bodysite, nodular status, metastatic status and Breslow 
thickness. Relative excess risks showed the expected patterns for all mentioned covariates 
[Table 2]. 
Since Breslow thickness has not been routinely registered during the period 89-93, this first 
period was not included in multivariate analyses. A multivariate model without Breslow 
thickness was fit over all four time periods, using the period 89-93 as a reference, showing 
decreasing RER of dying for the more recent periods [data not shown].  
Trends in mortality 
The absolute number of annual deaths due to melanoma increased from 337 in 1989 to 794 in 
2009. The age-standardised mortality rate due to melanoma increased from 2.2 per 100,000 
person years in 1989 to 3.9 per 100,000 person years in 2009  (EAPC 2.3, 95% CI: 2.0-2.6) 
[Figure 1]. Mortality rates in younger patients (0-44 year) remained stable over the years 
[Figure 3]. A significant increase in mortality was observed in patients aged 45 to 64 years. 
The steepest increase in mortality was observed in males and females older than 65 years 
(EAPC 4.1, 95% CI: 3.1-5.0 and 2.2, 95% CI: 1.4-3.0, respectively). 
 
Discussion 
The aim of our study was to assess concordance in time in trends of incidence, mortality and 
survival of cutaneous melanoma in the Dutch general population. The findings of this study 
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suggest that the melanoma incidence is truly rising and is not solely depending on increased 
diagnosis, because melanoma incidence among all Breslow categories increased as well as 
melanoma mortality.  
Trends in incidence 
An overall increase in incidence rate was observed, which is in line with results from many 
countries [2, 13-15]. However, in Australia and Canada incidence rates have been observed to 
be stabilizing or even decreasing in younger individuals [16-17], possibly as result of 
successful health care campaigns in avoiding sun exposure [17]. In most countries the 
increase in incidence rate is primarily due to an increase of thin melanomas while the 
incidence rate of thick melanomas is no longer increasing [18-19]. It has been debated that 
this epidemiologic pattern indicates early diagnosis due to improved awareness and possibly 
overdiagnosis by pathologists rather than a real increase in the disease. 
We observed an increase in thin as well as thick (>4 mm) melanomas. In females, the thick 
melanomas increased annually with the same percentage as thin melanomas. Similar results 
are reported in England and the USA among older patients (>65 years)[13, 15]. The observed 
increase over the whole spectrum of all stages of melanoma is an argument in favor of a real 
increase in incidence of disease [7]. Alternative explanations would include a more 
conservative approach of the pathologists or improvements in the cancer registry practices. 
The more conservative pathologist explanation would mainly result in increases in the thin 
melanomas. It is possible that the cancer registry has improved over time, resulting in a larger 
proportion of melanomas of all thicknesses appearing in the cancer registry. Indeed, in a study 
verifying data from 3 regional Dutch cancer registries from 1990 it was found that the 
completeness of skin malignancies (excluding basal cell carcinomas) was 92.9% [20]. 
However, the proportion of cases not being included in the database would largely depend on 
histopathology diagnosis, and presumably most of the 7.1% of ‘missed’ cases would be 
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squamous cell carcinomas. Moreover, an increase in completeness of the registry above the 
92.9% is unlikely to result in EAPCs as strong as observed among all thickness categories in 
our study. 
Although awareness of potential harmful effects of sun exposure has increased in the 
Netherlands in recent years [21], incidence rates of melanoma have not stabilized and are 
expected to rise even further [22]. Incidence rates were increasing most steeply in older 
patients (>65 years). Due to unawareness of potential harmful effects of sunlight in their 
younger years, these older patients could have accumulated high amounts of sun exposure and 
high number of sunburns during their (adolescent) lifetime. Prevention campaigns started at 
the end of the eighties, when the Dutch cancer society (KWF) started campaigns at the Dutch 
and Spanish beaches to increase awareness of risk factors for skin cancer among these high 
risk populations [personal communication][21].  
The largest incidence rates and mortality rates were observed in older patients. Therefore, 
future secondary prevention campaigns should aim to increase awareness in this high risk 
group. Although it might be difficult to reach specific subgroup of patients, targeted 
secondary prevention campaigns may be possible [23].  
Trends in survival 
The survival of Dutch melanoma patients has been described for three geographic regions in 
the Netherlands [24-25], showing that survival rates of females were significantly better and 
independent of patient’s demographics and classical melanoma characteristics. We observed 
an increase in 10-year relative survival for both sexes over time. In most European countries, 
the 5-year relative survival improved as well, with a relative increase varying from 1 to 30% 
[26]. In the observed time period no major improvements in the treatment of melanoma have 
been introduced. The improvements in relative survival may partly have been caused by 
increased awareness and earlier detection, which artificially prolongs survival time leading to 
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a lead time bias in the analysis [27]. Our multivariate survival analyses were adjusted for 
follow-up time of each patient to correct for lead time bias as much as possible. Observed 
changes in distribution of melanoma thickness, histological subtype and other prognostic 
factors could have caused the change in survival. Multivariate analysis on survival showed 
that period of diagnosis decreased relative survival, independent of changes in distribution of 
all known prognostic factors over time. This result might be caused by the introduction of the 
sentinel lymph node procedure for melanoma patients in 1992, although the effect on survival 
is still unclear and under evaluation [28]. Another possibility is that dermatologist and 
pathologists in more recent periods became more cautious and classified slightly atypical 
pigmented lesions more often as malignant melanomas [7]. This diagnostic drift leads to a 
bias of prolonged survival times in the more recent periods.  
It is expected that survival may improve even further in the future, particularly for advanced 
disease, because new promising therapies are currently tested in clinical trials [29]. These 
therapies include B-RAF inhibitors and cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) 
inhibitors. B-RAF is part of the mitogen-activated protein kinase (MAPK) pathway and is 
mutated in approximately 60% of all melanomas [30]. Increased expression of CTLA-4 
downregulates the immune response [31]. By inhibiting CTLA-4 the naturally occurring 
immune responses to tumor cells can be enhanced. Recently a phase III trial on ipilimumab 
was published, showing improved overall survival in patients with metastatic melanoma [32]. 
 
Trends in mortality 
We observed increased mortality rates, which is in contrast with findings in most other 
countries, where mortality rates remain stable over the years [14-15, 33]. As melanoma 
thickness is a strong predictor for disease progression, the observed increase in thick 
melanomas could have been the cause of the increased mortality rates [34-36]. In other 
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European countries, like England, France, Italy, Sweden and Poland, mortality rates increased 
as well [26, 37]. In our data mortality rates did not increase as rapidly as incidence rates, 
which could have been caused by the improved survival of melanoma patients. Incidence 
rates of patients diagnosed with metastatic melanomas did not increase over time, but 
mortality rates did increase during the study period and do not seem to stabilize [Figure 3]. 
This indicates that a subgroup of melanomas without distant metastasis at diagnosis 
metastasize over time leading to death.  
Increased incidence rates accompanied by increased mortality rates suggest a true increase in 
the amount of melanomas, rather then a potential overdiagnosis [6-7, 38]. We therefore state 
that the observed increase in incidence reflects a real increase of melanoma patients in the 
Netherlands, rather than an artifact which have been caused by diagnostic drift.  
 
Conclusion 
We observed increased incidence rates of melanoma in the Netherlands since 1989. This was 
due to the increase of thin as well as thick melanomas, which is a worrying trend as 
melanoma thickness is a strong predictor for prognosis [34-36]. The increase in incidence was 
accompanied by an increase in mortality. Survival improved over time independent of the 
distribution of all known prognostic factors. This pattern points at a real melanoma epidemic 
in the Netherlands. To improve survival and decrease incidence and mortality rates in the 
future, efforts should be made to increase primary and secondary prevention of melanoma. 
Primary prevention campaigns should aim at parents to protect their children from sunburns 
in childhood and adolescence. Secondary prevention campaigns should include older and 
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Figure 1: Three-year moving averages of age standardised incidence rates and mortality rates 
(ESR) of melanoma in the Netherlands, 1989-2008.  
 
Figure 2. Ten-year relative survival of melanoma in the Netherland by period of diagnosis 
and sex, 1989-2008 
 
Figure 3: Three-year moving averages of age standardised mortality rates (ESR) of 
melanoma by age of males (A) and females (B) in the Netherlands, 1989-2008. 
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Table 1. Age standardised incidence rates (ESR) of melanoma in the Netherlands, 1989-2008 

















EAPC (95% CI) 
Incidence                
Overall 21306 9.0 11.3 13.8 17.9 4.54 (4.01-4.97)  28889 12.2 14.6 17.2 21.5 3.72 (3.22-4.22) 
                
Age                
0-44 5758 2.6 3.0 3.4 4.1 2.80 (2.33-3.28)  10057 4.6 5.3 6.3 7.6 3.36 (2.78-3.94) 
45-64 9152 4.0 5.0 6.3 8.1 4.62 (4.02-5.22)  10846 5.2 6.3 7.4 9.2 3.73 (3.14-4.32) 
≥65 6396 2.3 3.2 4.2 5.7 5.98 (5.53-6.44)  7986 2.4 3.0 3.5 4.7 4.33 (3.64-5.02) 
                
Subtype                
SSM 10924 3.4 5.3 7.0 10.6 7.64 (7.05-8.22)  16388 5.4 7.9 10.3 14.3 6.50 (6.01-6.98) 
NM 3434 1.5 2.0 2.4 2.5 3.65 (2.84-4.47)  3626 1.6 1.9 2.1 2.2 2.08 (1.27-2.89) 
ALM 153 0.1 0.1 0.1 0.1 6.95 (2.77-11.13)  256 0.1 0.1 0.1 0.2 6.42 (3.67-9.16) 
LMM 652 0.3 0.4 0.4 0.5 4.43 (2.54-6.32)  944 0.3 0.4 0.5 0.6 5.74 (4.37-7.11) 
Other 6143 3.8 3.5 3.8 4.2 0.52 (-0.24-1.29)  7675 4.8 4.2 4.2 4.2 -0.95 (-1.67- -0.23) 
 
               
Bodysite                
Trunk 9815 4.1 5.0 6.3 8.5 4.95 (4.47-5.43)  7326 2.8 3.7 4.6 6.0 5.23 (4.80-5.65) 
Head/Neck 3465 1.5 1.9 2.4 2.7 3.77 (2.89-4.66)  3219 1.3 1.5 1.7 2.0 2.95 (2.43-3.47) 
Legs 3406 1.5 1.9 2.2 2.8 3.98 (3.20-4.77)  11306 5.2 5.8 6.9 8.1 2.98 (2.31-3.66) 
Arms 3455 1.3 1.8 2.2 3.0 5.40 (4.57-6.22)  6112 2.5 3.0 3.5 4.7 4.09 (3.27-4.90) 
Other 1165 0.6 0.6 0.8 0.9 2.69 (1.67-3.71)  926 0.5 0.5 0.5 0.6 1.59 (0.35-2.83) 
                
Breslow 
thicknessb 
               
<= 1 mm 7162  3.9 5.2 7.8 7.01 (6.10-7.92)  11960  6.5 9.0 11.9 6.14 (5.35-6.92) 
1.01-2 mm 3686  1.9 3.0 3.8 6.81 (5.56-8.06)  4873  2.5 3.7 4.7 6.16 (5.41-6.91) 
2.01-4 mm 2805  1.5 2.3 2.8 6.19 (4.82-7.56)  2769  1.4 2.0 2.4 5.37 (3.92-6.83) 
>4 mm 1909  1.1 1.6 1.9 5.26 (4.05-6.47)  1547  0.7 1.0 1.2 6.51 (5.12-7.89) 
 17
Unknown 2490  2.9 1.7 1.6 -5.13 (-7.55- -2.72)  2857  3.5 1.5 1.3 -8.23 (-11.5- -4.96) 
                
Nodular status                
TNM-N0/X 19710 8.6 10.6 12.6 16.3 4.22 (3.77-4.67)  27672 12.0 14.1 16.3 20.4 3.46 (2.95-3.97) 
TNM-N1+ 1596 0.4 0.7 1.2 1.5 9.12 (7.60-10.64)  1217 0.2 0.4 0.9 1.1 11.53 (9.78-13.28) 
                
Metastatic status                
TNM-M0/X 21036 8.8 11.1 13.6 17.7 4.59 (4.16-5.03)  28695 12.1 14.4 17.2 21.4 3.74 (3.23-4.26) 
TNM-M1+ 270 0.1 0.2 0.2 0.1 0.10 (-2.09-2.29)  194 0.1 0.1 0.1 0.1 0.88 (-1.78-3.54) 
  
    
          
  
a
 values may not add up to 100% of all melanomas due to missing values. 
b Breslow thickness was routinely registered since 1994. 
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Table 2. Multivariate relative survival analysis of melanoma in the Netherlands, 1989-2008 
 Males  Females 
 Univariatea   Multivariatea,b  Univariatea  Multivariatea,b 
 RER 95% CI  RER 95% CI  RER 95% CI  RER 95% CI 
Period of diagnosis                
1989-1993 1      1     
1994-1998 0.88 (0.79- 0.98)  1   0.84 (0.74- 0.96)  1  
1999-2003 0.81 (0.72- 0.90)  0.90 (0.82- 0.99)  0.75 (0.65- 0.85)  0.92 (0.82- 1.03) 
2004-2008 0.69 (0.62- 0.78)  0.83 (0.75- 0.92)  0.69 (0.59- 0.80)  0.88 (0.77- 1.00) 
            
Age                
00-44 1   1   1   1  
44-64 1.27 (1.16- 1.38)  1.25 (1.14- 1.38)  1.41 (1.27- 1.56)  1.29 (1.15- 1.45) 
65+ 1.83 (1.66- 2.02)  1.61 (1.45- 1.79)  2.55 (2.27- 2.86)  1.78 (1.57- 2.03) 
   
  
    
  
 
Subtype                
SSM 1   1   1   1  
NM 4.45 (4.01- 4.93)  1.30 (1.17- 1.46)  6.01 (5.24- 6.89)  1.42 (1.23- 1.64) 
ALM 3.50 (2.38- 5.15)  1.37 (0.90- 2.09)  5.64 (3.91- 8.13)  2.61 (1.81- 3.76) 
LMM 0.35 (0.15- 0.85)  0.27 (0.11- 0.70)  0.77 (0.38- 1.55)  0.16 (0.03- 0.77) 
Other 4.10 (3.73- 4.51)  1.40 (1.26- 1.56)  5.13 (4.54- 5.81)  1.51 (1.33- 1.73) 
            
Bodysite                
Trunc 1   1   1   1 . 
Head/Neck 1.22 (1.09- 1.36)  0.98 (0.87- 1.11)  0.980 (0.83- 1.16)  0.84 (0.71- 1.00) 
Legs 0.99 (0.89- 1.11)  0.82 (0.73- 0.93)  0.53 (0.47- 0.61)  0.54 (0.48- 0.61) 
Arms 0.70 (0.61- 0.80)  0.70 (0.61- 0.80)  0.52 (0.44- 0.61)  0.47 (0.40- 0.56) 
Other 7.46 (6.78- 8.20)  4.07 (3.54- 4.68)  9.26 (8.20- 10.46)  4.32 (3.59- 5.20) 
   
  
    
  
 
Breslow thickness                
<= 1 mm 1   1   1   1  
1.01-2 mm 7.19 (5.35- 9.67)  5.26 (4.08- 6.78)  7.44 (5.45- 10.15)  5.54 (4.21- 7.28) 
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2.01-4 mm 20.43 (15.39- 27.12)  11.39 (8.88- 14.61)  21.06 (15.57- 28.48)  10.87 (8.25- 14.32) 
>4 mm 36.40 (27.43- 48.29)  17.15 (13.32- 22.09)  54.73 (40.60- 73.79)  21.53 (16.25- 28.53) 
Unknown 29.93 (22.58- 39.66)  10.20 (7.92- 13.14)  25.20 (18.69- 33.98)  8.68 (6.56- 11.49) 
   
  
    
  
 
Nodular status                
TNM-N0/X 1   1   1   1  
TNM-N1+ 4.70 (4.32- 5.11)  2.32 (2.10- 2.56)  7.77 (6.97- 8.67)  2.87 (2.53- 3.26) 
   
  
    
  
 
Metastatic status                 
TNM-M0/X 1   1   1   1  
TNM-M1 17.25 (15.01- 19.81)  7.00 (5.95- 8.23)  31.26 (26.31- 37.13)  7.31 (5.97- 8.96) 
            
 
aThe analysis is adjusted for follow-up time 
bThe first period could not be included in the multivariate model, because Breslow thickness was not routinely registered before 1994 
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Figure 1: Three-year moving averages of age standardised incidence rates and mortality rates 
(ESR) of melanoma in the Netherlands, 1989-2008.  
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Figure 2. Ten-year relative survival of melanoma in the Netherland by period of diagnosis 














Figure 3: Three-year moving averages of age standardised mortality rates (ESR) of 
melanoma by age of males (A) and females (B) in the Netherlands, 1989-2008. 
